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Abstract: There has been much recent excitement about the possibility that some cases of
psychosis may be wholly due to brain-reactive antibodies, with antibodies to N-Methyl-
D-Aspartate receptor(NMDAR) and the voltage gated potassium channel(VGKC)-
complex reported in a few patients with first episode psychosis(FEP).
Methods
Participants were recruited from psychiatric services in South London,UK, from 2009-
2011 as part of the Genetics and Psychosis(GAP)study.
We conducted a case control study to examine NMDAR and VGKC-complex antibody
levels and rates of antibody positivity in 96 patients presenting with FEP and 98
controls matched for age and sex. LGI1 and CASPR antibodies were also measured.
Notably,patients with suspicion of organic disease were excluded.
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VGKC-complex antibodies were found in both cases(n=3) and controls(n=2). NMDAR
antibody positivity was seen in one case and one control. Either LGI1-Abs or CASPR2-
Abs were found in three cases and three controls. Neuronal antibody staining,
consistent with the above results or indicating potential novel antigens, was overall
positive in four patients but also in six controls.  Overall, antibody positivity was at low
levels only and not higher in cases than in controls.
Conclusions
This case-control study of the prevalence of antibodies in FEP does not provide
evidence to support the hypothesis that FEP is associated with an immune-mediated
process in a subgroup of patients. Nevertheless, as other bio-clinical factors may
influence the effect of such antibodies in a given individual, and patients with organic
neurological disease may be misdiagnosed as FEP, the field requires more research to
put these findings in context.
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Abstract 
Background 
There has been much recent excitement about the possibility that some cases of psychosis may be 
wholly due to brain-reactive antibodies, with antibodies to N-Methyl-D-Aspartate receptor (NMDAR) 
and the voltage gated potassium channel (VGKC)-complex reported in a few patients with first episode 
psychosis (FEP).  
Methods 
Participants were recruited from psychiatric services in South London, UK, from 2009-2011 as part of 
the Genetics and Psychosis (GAP) study.   
We conducted a case control study to examine NMDAR and VGKC-complex antibody levels and rates 
of antibody positivity in ninety-six patients presenting with FEP and ninety-eight controls matched for 
age and sex. LGI1 and CASPR antibodies were also measured. Notably, patients with suspicion of 
organic disease were excluded.  
Results 
VGKC-complex antibodies were found in both cases (n=3) and controls (n=2). NMDAR antibody 
positivity was seen in one case and one control. Either LGI1-Abs or CASPR2-Abs were found in three 
cases and three controls. Neuronal antibody staining, consistent with the above results or indicating 
potential novel antigens, was overall positive in four patients but also in six controls.  Overall, antibody 
positivity was at low levels only and not higher in cases than in controls.  
Conclusions 
This case-control study of the prevalence of antibodies in FEP does not provide evidence to support the 
hypothesis that FEP is associated with an immune-mediated process in a subgroup of patients. 
Nevertheless, as other bio-clinical factors may influence the effect of such antibodies in a given 
individual, and patients with organic neurological disease may be misdiagnosed as FEP, the field 
requires more research to put these findings in context.   
 
Keywords: First episode psychosis; FEP; NMDA; VGKC-complex; schizophrenia; antibodies 
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Title:  
Brain-relevant antibodies in First Episode Psychosis: A matched case-control study 
Introduction 
The link between psychosis and autoimmunity has been explored over many decades (Benros et al., 
2014, Eaton et al., 2006, Wright et al., 1999), but only in recent years has this been related to the 
pathophysiology of psychosis at a neurotransmitter level via specific antibodies against antigens 
which have clearly established links to the aetiology of psychosis.  This has resulted in a surge of 
interest in whether a sub-group of people with psychosis have serum antibodies to certain neuronal 
antigens, although the specificity, sensitivity and clinical relevance of these remain unclear (Coutinho 
et al., 2014, Deakin et al., 2014, Pollak et al., 2014). These auto-antibodies target synaptic or extra-
synaptic membrane-expressed proteins, with greatest interest in antibodies to the N-Methyl-D-
Aspartate receptor (NMDAR) and the voltage gated potassium channel (VGKC)-complex, which 
includes antigens  leucine- rich glioma inactiviated-1(LGI1) and contactin-associated protein-2 
(CASPR2) (Ezeoke et al., 2013, Pearlman and Najjar, 2014, Steiner et al., 2013, Zandi et al., 2011).   
Psychotic symptoms are a common feature of the encephalitis syndromes classically associated with 
such antibodies – often occurring before the development of other features of encephalitis, such as 
seizures, movement disorders, autonomic instability and impaired consciousness.  For example, in the 
seminal case series describing 100 anti-NMDAR encephalitis cases, the majority (77%) of patients 
initially presented to psychiatry services with predominantly psychotic symptoms (Dalmau et al., 
2008). A subsequent larger case series of 571 patients reported 18 patients (3.2 %) having an 
‘isolated’ psychiatric relapse (after an initial ‘full’ encephalitis). Five further patients (0.9 %) had 
‘isolated’ psychiatric symptoms, again predominantly psychosis, at presentation – although on 
retrospective close examination they were found to have had other clinical features and were re-
diagnosed as encephalitis (Kayser et al., 2013). The key question is therefore whether isolated 
psychosis, i.e. schizophrenia, is associated with these antibodies. 
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A prospective cohort study in first episode psychosis (FEP) identified serum NMDAR antibodies in 
6.4% of patients (n=3/47) (Zandi et al., 2011) using a live cell-based assay (CBA) and well-
established subjective visual scoring system (Irani et al., 2010b). A recent case-control study in FEP 
identified an increased prevalence of NMDAR antibodies (n=7/228; 3% of total population) compared 
to controls (n=0/105), with no difference in the prevalence of LGI1, CASPR2 or VGKC-complex 
antibodies between the groups (Lennox et al., 2017). Using the same methodology, a recent study by 
our group found that 7% of patients (n=3/43) with chronic refractory psychosis were positive for 
NMDAR antibodies (Beck et al., 2015). Methodology, however, appears to be relevant, as 9.9% of 
patients with acute schizophrenia were reported NMDAR antibody positive using the commercial 
fixed CBA, with similar rates in controls (Steiner et al., 2013), whereas, other studies have failed to 
identify any antibody positivity in either FEP (Masdeu et al., 2012) or established schizophrenia (de 
Witte et al., 2015, Haussleiter et al., 2012, Rhoads et al., 2011). Some of these negative studies also 
used fixed CBA to measure NMDAR seropositivity, but there have been few direct comparisons 
between laboratories (Wandinger et al., 2011).  A meta-analysis identified no excess of NMDAR 
antibody (of any subtype (IgG, IgM, IgA)) in psychotic disorders, though IgG antibodies alone were 
significantly greater in FEP cases (IgG positive in 5/272 of cases) than in controls (IgG positive in 
5/1598 of controls) (Pollak et al., 2014).   
VGKC-complex antibodies can also cause cell-surface antibody associated CNS disorders (Zuliani et 
al., 2012). Most of these antibodies bind to LGI-1 or CASPR-2 (Irani et al., 2010a), which are cell 
surface proteins that form part of the VGKC-complex. The targets of other VGKC-complex 
antibodies are unclear, although two recent studies suggest that they bind to intracellular epitopes and 
may be neuroinflammatory biomarkers rather than pathogenic antibodies (Hacohen et al., 2015, Lang 
et al., 2017).   
Many patients with high levels of VGKC-complex antibodies have evidence of limbic encephalitis 
and some present first with psychosis (Paterson et al., 2014).  Phenotypically, LGI1 antibodies tend to 
associate with limbic encephalitis and faciobrachial dystonic seizures, phenomena which can be 
misinterpreted as myoclonic jerks (Irani et al., 2011). CASPR2 antibodies, meanwhile, are associated 
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with neuromyotonia or Morvan's syndrome in which psychiatric features are common, often with a 
thymoma (Irani et al., 2010a). In a case series, over a third of patients with VGKC-complex 
antibodies had psychiatric symptoms, including confusion, personality change, memory impairment 
and depression (Somers et al., 2011).  Those affected are classically older than those with NMDAR 
antibody encephalitis. VGKC-complex antibodies were identified in one patient out of 46 with FEP 
(Zandi et al., 2011).  
The importance of antibodies to NMDAR and VGKC-complex proteins is clear when psychosis 
presents in the context of encephalitis, but the challenge in psychiatry is to determine their relevance 
in clinically uncomplicated psychosis.  Only one study to date has compared the prevalence of both 
these, and other neuronal antibodies in adults with FEP compared to matched controls (Lennox et al., 
2017).  
 
Methods and Materials 
 
Participants  
The study population comprised 96 adults with a FEP and 98 matched controls. The participants were 
recruited as part of the Genetics and Psychosis (GAP) study.  The GAP study is a case-control study 
investigating the genetic basis of susceptibility to psychosis. 
Participants were recruited from both inpatient and outpatient settings through working closely with the 
clinical teams. Patients were consented as soon after first presentation with psychosis as possible (the 
mean duration from the time of first contact for psychosis to the time of blood sampling was 52.74 
(SD=37.3) days (median 47 days ; range 7-167 days)). Assessments were performed by trained research 
workers and Operational Criteria Checklists (OPCRIT) diagnoses made by research clinicians. 
Participants were aged 18-65 years. Patients were eligible if they had a first episode psychosis and met 
the ICD-10 criteria for psychosis (ICD-10 codes F20-29 and F30-33) diagnosed utilising the OPCRIT 
(McGuffin et al., 1991). The baseline diagnoses were made from face-to-face interviews by trained 
researchers and mental health records according to ICD-10 criteria (WHO, 1992) utilising the OPCRIT 
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(McGuffin et al., 1991).  Participants had made first contact with our health services for psychotic 
symptoms not more than 12 months previously. 
Study Design  
Patients were matched for gender and age (plus or minus 5 years) to 98 healthy controls from the same 
local population, recruited by means of internet and newspaper advertisements, and distribution of 
leaflets at train stations, shops and job centres. Those who agreed to participate as controls were 
administered the Psychosis Screening Questionnaire (Bebbington and Nayani, 1995) and excluded if 
they met criteria for a psychotic disorder or reported a previous diagnosis of psychotic illness.  
Exclusion criteria for both controls and cases were an organic psychosis (ICD-10: F06.8 and F9.0), i.e 
a psychosis deemed likely to be secondary to neurological disorders such as epilepsy, head injury, or to 
a long term deterioration of intellectual function and memory (dementia) or a short term disturbance of 
orientation, judgement, or consciousness (delirium). The Schedule for Clinical Assessment in 
Neuropsychiatry (SCAN) was administered to elucidate psychotic symptoms present in the month 
before study recruitment, from which those cases meeting criteria for organic psychosis were excluded. 
These decisions were made in discussion with two experienced psychiatrists. Those with a substance 
induced psychosis as defined by ICD-10, a diagnosis of intellectual disability, terminal cancer, and 
pregnancy were also excluded.  
All participants provided written informed consent. The project was approved by the Research Ethics 
Committee of the Joint South London and Maudsley and The Institute of Psychiatry NHS Research 
Ethics Committee.   
Specimen Collection  
The samples were transferred to Oxford for testing in two batches during the course of the 
observational study. The first group consisted of plasma from 30 patients and 30 age and sex matched 
controls while the second group was serum from 66 patients and 68 controls matched for age and sex.   
Plasma samples 
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Samples were collected in EDTA tubes using a 23 gauge butterfly needle and vacutainer needle 
holder following standard venepuncture in the cubital region, in the area of anastomosis between the 
radial and the ulnar veins or in the brachial vein, slightly proximal to this area. To avoid coagulation 
of the sample, a 9ml K3EDTA tube (Greiner Bio-One, Cat # 455036X - EDTA tube, lavender lid) 
was used. The sample was immediately kept at +4°C until being processed within two hours. The tube 
was labelled with the subject barcode with no phenotypic information given and then centrifuged at 
3000 rcf (xg), 8 minutes at +4°C; the plasma was aliquoted in 0.5 ml eppendorf tubes and frozen at -
80°C within three hours of collection.  
Analysis of results for combined plasma and serum samples (n=194), and with serum samples alone 
are presented (n=134).   
Antibody testing   
All samples received in Oxford were kept at -20 C until the analyses, blinded to patient-control status, 
were performed.   The antibody assays for NMDAR, LGI1 and CASPR2 were performed using live 
cell-based assays as established in previous studies (Irani et al., 2010a, Irani et al., 2010b, Zandi et al., 
2011) and as used for routine diagnostic testing for the Oxford Neuroimmunology Service.  HEK293 
cells were transfected with plasmids encoding the human forms of NMDAR (NR1 and NR2B 
subunits), LGI1 or CASPR2, washed, grown for 24-36 hours and then incubated at room temperature 
in the plasmas or sera at 1:20 (1:100 for CASPR2 as used routinely for this protein). Binding of 
antibodies to the transfected antigens on the live cells was detected with Alexa fluor labelled anti-
human IgG, and the cells examined under fluorescence microscopy. The binding was compared with 
known positive and negative controls and scored on a scale from 0 – 4.    
Positive results (>0) were repeated and the IgG specificity confirmed with an IgG-specific CBA.  This 
involved replacing anti-human IgG, which can recognise the light chains of IgG, A, M and D, with 
goat anti-human Fc IgG secondary (Thermo Scientific; 31125; 1:750), followed by mouse anti-goat 
IgG, Alexa fluor 568 (1:750) for 45 minutes at room temperature (Pettingill et al., 2015). Full details 
are given in (Pettingill et al., 2015) and in the Appendix (supplementary material 1). 
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Serum VGKC-complex antibodies were tested using a radio-immunoprecipitation assay (Irani et al., 
2010b, Paterson et al., 2014). VGKC results were expressed as picomoles (pM) per litre of serum.  
Neuronal cultures were prepared from P0 rat hippocampi and antibody binding performed at 1:100 
serum or plasma after 10-14 days in culture (Irani et al., 2010a, Irani et al., 2010b, Pettingill et al., 
2015). 
Clinical assessments 
The degree of psychopathology at first presentation to mental health services was measured on the 
Positive and Negative Syndrome Scale (PANSS)(Kay et al., 1987). Overall functional disability was 
assessed using the Global Assessment of Functioning (GAF).  
 
Statistical Analysis 
Differences in NMDAR and VGKC-complex antibody prevalence rates in FEP patients and controls 
were assessed using Chi square and t-tests. All statistical tests were two-sided and the α- level for 
statistical significance was 0.05.   
Results 
Sample characteristics 
The demographic characteristics of patients with FEP and controls are shown in Table 1.  
Cases and controls with positive results are summarized in Table 2.  Six percent of cases (n=6/96) and 
6% of controls (n=6/98) were positive (x2=0.001, p=0.602) for specific antibodies (NMDAR, LGI1, 
CASPR2 or VGKC-complex); of these, three cases and three controls had IgG antibodies binding to 
hippocampal neurons in culture.  An additional one case and three controls had unknown neuronal 
antibodies only.  Overall, nine controls and seven patients had antibody positivity or were positive on 
neuronal staining, but this difference did not meet statistical significance (x2=0.229, p=0.414). All 
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patients with antibody positivity or positive neuronal staining were female (7/47). Five controls with 
antibody positivity or with neuronal staining were female and 3 were male. Examples of the cell-based 
assays, neurons and scatter plots of the data are shown in supplementary figure 1. 
Of the plasma samples, no antibody positive cases were detected in cases (n=30), but one female control 
sample was positive for LGI1, with no other antibodies identified in control plasma samples (n=30). 
When the serum samples alone were considered, therefore, the proportion with antibody positivity or 
neuronal positivity increased to 8/68 controls (11.8%) and 7/66 patients (10.6%) x2=0.045, p=0.525)  
NMDAR Antibodies 
Standardised immunofluorescent cell based assay (CBA) for the detection of serum IgG antibodies 
directed against NMDAR was positive in 1% (n=1 female) of cases and 1% (n=1 male) of controls.  
VGKC-complex, LGI1 and CASPR2 antibodies  
VGKC-complex antibodies were the most prevalent antibody in both cases and controls, found in 3.1% 
(n=3) of patients and in 2.0% (n=2) of controls (x2=0.227, p=0.490). In cases, VGKC-complex antibody 
positivity was found in female patients only (n=3/47) (males (n=0/49) (x2=3.229, p=0.113)). VGKC-
complex antibodies were found in one male and one female control.  
Two patients (both female) and two controls (both female) had LGI1 antibodies, though none were 
associated with VGKC-complex antibodies. CASPR2 antibodies were found in one female patient and 
in one female control. The patient with CASPR2 antibodies was also positive for NMDAR antibodies. 
There were no cases or controls with high positive VGKC-complex antibodies. (>400pM). The mean 
level in cases was 179.7 (SD 95.8) pM and 212.0 (SD 31.1) pM in controls (t=0.441, p=0.689). One 
case with VGKC-complex antibodies (132 pM) and one control (234 pM) also showed neuronal 
staining.  
Associations with clinical measures 
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There were no significant differences between cases with any antibody positivity and cases which 
were antibody negative in mean total PANSS score (64.2 (15.4) vs 59.3 (15.1) (z=0.460, p=0.646); 
mean PANSS positive scores (18.8 (3.9) vs 15.2(6.0) (z=1.582, p=0.114); mean PANSS negative 
score (13.2 (6.6) vs 13.9 (5.3) (z=-0.607, p=0.544); mean GAF symptom scores (29.6 (12.4) vs 28.9 
(12.6) (z=0.335, p=0.737) or mean GAF disability scores (30.1 (14.7) vs (31.9 (14.4) (z=-0.502, 
p=0.616).  
 
Discussion 
This is the second matched case-control study to assess the prevalence of antibodies in patients with 
FEP and matched healthy controls. We did not find evidence to support the hypothesis that FEP is 
associated with an immune-mediated process in a subgroup of patients.  Our findings in healthy adults 
contrast with those of the recent case control study of 228 FEP patients, in which NMDAR antibodies 
(n=7; 3% of total population) were more prevalent in patients with FEP than in the control group 
(n=0/105) (Lennox et al., 2017). Similar to our study, Lennox et al did not identify a significantly 
increased prevalence of antibodies against LGI1, or VGKC-complex between the groups. Our rates of 
patient positivity were similar to, and indeed slightly numerically higher than an earlier case series 
(Zandi et al., 2011), but no higher than in our controls. Our findings therefore fail to support the 
hypothesis that NMDAR and VGKC-complex antibodies are higher or more prevalent in the sera of 
patients with FEP than in healthy controls.  
This accords with findings in other centres: Steiner et al. 2013 found no difference in NMDAR 
antibody rates between groups in a large cohort of people with acute schizophrenia and controls, 
although the laboratory methods were different to those used here. A large scale systematic screening 
did not identify a significant difference in prevalence of NMDAR antibodies between those with 
schizophrenia (8.6%) and healthy controls (10.8%)(Hammer et al., 2014). In that study, the authors 
postulated that those with schizophrenia may be rendered vulnerable to the effect of circulating 
antibodies by previous blood brain barrier perturbation, perhaps due to previous head injury or 
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infection(Hammer et al., 2014). Likewise, a smaller unmatched case control study found no NMDAR 
antibodies in either 80 patients with first episode schizophrenia or 40 controls (Masdeu et al., 2012). 
Our findings in healthy adults contrast with those of a case control study of 43 children with FEP 
(median age 15 years), which identified NMDAR antibodies in 6 of 43 patients, but in none of the 
controls (Pathmanandavel et al., 2014).  
While we did not find it to be statistical significant, it is intriguing that all 7 patients with antibody or 
neuronal positivity were female. A predominance of females with NMDAR antibodies is evident in 
patients with NMDAR-antibody encephalitis with 59% of such cases associated with ovarian tumours 
(Dalmau et al., 2008).  However, subsequent reports tended to find less extreme gender effects (68% 
female vs 32% males) and lower rates of ovarian tumours (26% of females with NMDAR antibody 
positivity with ovarian teratoma)  (Irani et al., 2010b).  Our findings are not consistent with prior 
studies in established psychosis, in which male patients with antibody positivity prevailed (Steiner et 
al: 10 male vs 5 female positive; Hammer et al: 11.5% male positive and 8.7% females)(Hammer et 
al., 2014, Steiner et al., 2013) and there were equivalent prevalence of IgA and IgM antibodies in 
cases and controls(Hammer et al., 2014).  We identified no difference in IgG antibodies, which are 
considered highly specific for the full NMDAR-antibody encephalitis, between patients and controls.  
Our study excluded people presenting with organic psychosis, and so our sample may have fewer 
patients with neurological/neuropsychiatric features than a less selected group. Nevertheless, if serum 
disease relevant autoantibodies result in uncomplicated psychosis, one would expect to see an excess 
of these antibodies in the patient group over controls. We did not, however, test for other factors 
which may render serum antibodies pathological in patients, such as those affecting blood brain 
barrier permeability(Hammer et al., 2014), and there is evidence from case series that NMDAR-
antibody positive patients with predominant psychosis at onset can be missed or have delayed 
diagnosis (Barry et al., 2011, Tsutsui et al., 2012).   
We restricted our search to IgG antibodies detected on the cell based assays (NMDAR, LGI1, 
CASPR2) and did not look specifically for other (e.g., IgM, IgA) antibody classes.  Although the IgG 
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antibody subtype was the class that was associated with psychosis in a meta-analysis of NMDAR 
antibody prevalence in FEP (Pollak et al., 2014), it remains possible that subjects with FEP and 
controls in this study could differ with respect to other antibody classes.   Another potential source of 
underestimate in antibody prevalence in cases was that only serum or plasma was tested. It has 
previously been shown that in NMDAR-antibody disease 15% of patients with antibodies in the 
cerebrospinal fluid (CSF) did not have detectable antibodies in the serum (Gresa-Arribas et al., 2014), 
although that study used a different method to that used here; nevertheless it would be important in 
future studies to obtain CSF.  
It has been suggested that differing findings in the field may relate to this variation in methodologies 
(Masdeu et al., 2012, Rhoads et al., 2011). All are based on visualisation of staining, where serum 
antibody is reacting with a transfected cell expressing the antigen in a natural conformation, but many 
use fixed permeabilised cells, which may reduce sensitivity and potentially may reduce specificity.    
We noted the absence of antibody reactivity in all the plasma samples in cases. This may reflect a true 
absence of positive samples or could result from an unidentified technical problem. Antibodies can be 
tested adequately in plasmapheresis samples but the plasma samples were collected in EDTA tubes; it 
is theoretically possible that this may have affected the live cell assays. We decided that it was 
important to report this group as, were we to exclude them, while the proportion of positive cases and 
controls would increase further, there would still be no difference between groups.  
During the course of the study patients with organic presentations were excluded which may be one 
reason for the low proportion of positive results in comparison with Lennox et al 2017(Lennox et al., 
2017). Further, as the proportion of cases and of controls with antibody positivity was small, it 
remains a possibility that the negative findings may be due to insufficient statistical power. We do not 
have longitudinal data in relation to outcomes for these patients and none of the patients received 
immunotherapy concurrent to the identification of antibody positivity. We did not set out to describe 
clinical impact and course of illness in those with antibody positivity.   
Conclusions 
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We have identified a similar low prevalence of NMDAR and VGKC-complex antibodies in patients 
with first episode psychosis as in controls. Thus screening of patients with FEP for these antibodies in 
isolation will generate results that may be difficult to interpret in practice. Further work is needed to 
understand what other conditions, either clinical or biological, need to exist to render such antibodies 
clinically relevant in psychosis.   
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Figure 1. Cell-based assays and scatter plots of the data 
 
Left.  Examples of cell based assays for antibodies to CASPR2, LGI1 and NMDAR 
antibodies, and binding to live neuron.   
In A. green fluorescent protein is used to indicate the transfection rates (left panels), red 
indicates the human IgG binding (central panels), and the merged images are shown in the 
right panels x40; and at higher magnification on the very right (x100).   
B. Examples of sera binding to hippocampal neurons from one case, one control and one 
healthy individual.  Human IgG is detected with green fluorescence, and after washing, fixing 
and permeabilisation the neurons are stained red with anti-MAP2.   
C. Results of the antibody (Ab) screening assay (with anti-IgG(H&L) and the IgG specific 
assay (with anti-IgG(Fc)).  The latter was only performed on the 14 of 16 sera still available 
in sufficient volume. Scores are shown for NMDAR and LGI1 antibodies at 1:20, and 
CASPR2 antibodies at 1:100, as performed for routine diagnostic analysis.  
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Table 1: Characteristics of patients with first-episode psychosis and control participants 
 Patients with  
first episode psychosis (n=96) 
Control group 
(n=98) 
Sex 
 Male 
 Female 
 
49 (51%) 
47 (49%) 
 
49 (50%) 
49 (50%) 
Age (years) 
Mean (SD) 
Median (range) 
 
32.7 (10.7) 
30 (18-63) 
 
32.2 (11.0) 
29 (18-59) 
Ethnicity 
White 
Black 
Asian 
Other 
 
51 (53%) 
30 (32%) 
10 (10%) 
5 (5%) 
 
58 (59%) 
26 (27%) 
11 (11%) 
3 (3%) 
Diagnoses 
Paranoid Schizophrenia 
Mania with psychotic symptoms 
Schizoaffective disorder 
Severe depression with psychotic symptoms 
Delusional disorder 
Other(including unspecified nonorganic psychosis) 
 
 
 
47 (49%) 
12 (13%) 
9 (9%) 
9 (9%) 
3 (3%) 
16 (17%) 
 
Data are n (%) unless otherwise specified. 
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Table 2: Demographic and clinical characteristics of antibody positive cases and controls  
 
 
 
NMDAR=N-Methyl-D-Aspartate receptor; LGI1= leucine- rich glioma inactiviated-1; CASPR= 
contactin-associated protein-2; VGKC-Ab = voltage gated potassium channel-complex antibody (by 
radioimmunoassay); M=male; F=female 
CASES Demographics ICD-10      
Diagnosis 
 CONTROLS Demographics 
Antibody(ies) 
detected 
   Antibody(ies) 
detected 
 
Hippocampal 
neurons 
NMDAR-Ab, 
score 2.5 at 1:20 
CASPR2-Ab, 
score 2 at 1:100 
F/58/White Paranoid 
schizophrenia 
 Hippocampal 
neurons 
NMDAR-Ab, 
score 1 at 1:20 
 
M/30/Black 
Hippocampal 
neurons 
LGI1-Ab, 2.5 at 
1:20 
 
F/23/Black Paranoid 
schizophrenia 
 Hippocampal 
neurons 
LGI1-Ab, score 
1.5 at 1:20 
F/22/White 
LGI1-Ab, score 
2 at 1:20, no 
sample available 
for confirmation 
 
F/28/Black 
 
Schizoaffective 
disorder, manic 
type 
 LGI1-Ab, no 
sample available 
for confirmation 
 
F/36/White 
Hippocampal 
neurons 
VGKC132 pM 
 
F/44/Black No criteria met  Hippocampal 
neurons 
VGKC 234 pM 
 
F/31/Asian 
VGKC-Ab 117 
pM only 
 
F/41/White Schizoaffective 
disorder, depressive 
type 
 VGKC 190 pM 
only 
 
M/42/Black 
VGKC-Ab 290 
pM only         
F/18/White Paranoid 
schizophrenia 
   
    CASPR2-Ab, 
score 2 at 1:100 
 
F/37/White 
Hippocampal 
neurons 
 
F/24/White Schizoaffective 
disorder, manic 
type 
 Hippocampal 
neurons 
 
F/25/White 
    Hippocampal 
neurons 
 
F/46/Black 
    Hippocampal 
neurons 
 
M27/Black 
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Supplementary Material 1  
Appendix  
HEK 293 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM; Sigma D6429) 
supplemented with 10% Fetal Calf Serum (FCS; Biowest S181B) and 1% penicillin 
G/streptomycin/amphotericin (PSA; Life technologies 15240-062) in flasks kept in a 
humidified, 5% CO2 incubator. For screening purposes, those cells grown in flasks were 
transferred to 6-well plates with 13 mm poly-l-lysine coated glass coverslips, by gentle 
detachment with 1% trypsin in phosphate buffer saline (PBS) and re-seeding in DMEM/10% 
FCS/1% PSA at a concentration of 2.5 x 105 cells/mL, in a total volume of 2 mL/well. The 
following day, cells were transfected using 1.5 l polyethylenimine (PEI) with 3 g of the 
cDNA plasmids encoding the relevant human subunits. After 14-16 hours, the medium was 
replaced with fresh DMEM/10% FCS/1% PSA. In the particular case of the NMDAR CBA, 
to prevent cytotoxicity as a result of glutamate in the medium activating the NMDARs, the 
medium was supplemented with 500 M of ketamine. Immunocytochemistry (ICC) was 
performed on the fourth day. Up until then, all procedures were conducted in sterile 
conditions in a class II tissue culture hood. For ICC, coverslips were transferred to individual 
wells in a 24-well plate. Patient serum samples were added to DMEM supplemented with 
bovine serum albumin (BSA) (1% w/v) and 200 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, Sigma H3375) at a 1:20 or 1:100 dilution ratio, to 
make a total volume of 250 μl/sample. Positive (known positive patients) and healthy 
controls were added in each assay. Diluted sera were incubated with the live cells on 
coverslips at room temperature for 1 hour, after which the supernatant was aspirated and 
washed 3 times in DMEM/HEPES. Cells were fixed in 4% formaldehyde in PBS and 
incubated for 10 minutes at RT and then washed 3 times in DMEM or PBS. Afterwards, 
cultures were incubated for 45 minutes in the dark, at room temperature, with goat anti-
human IgG, Alexa Fluor 568 (Invitrogen; A21090; 1:750) in DMEM+HEPES+BSA. The 
coverslips were washed 4 times in PBS and mounted using fluorescent mounting media 
(Dako, S3023), containing 4',6'-diamidino-2-phenylindole (DAPI; Sigma D9542; 1:1000). 
After drying, cells were viewed with a Leica DM 2500 immunofluorescent microscope. 
Binding was then scored on a scale of 0-4 according to the intensity of the 
immunofluorescence (0= no binding, 1= weak binding, 2= moderate binding, 3=strong 
binding, 4=very strong binding). Any sample scoring 1 or above was repeated and double 
scored by a second, independent observer. If there was disagreement between observers, the 
sample would be retested. Positive samples (score ≥1) were then titrated and end-point 
titration determined (last titration at which a score=1 was still observed). Case and control 
samples were screened blinded to clinical status. 
To confirm positive samples and the IgG nature of the binding, the live CBAs were repeated 
replacing goat anti-human IgG, Alexa Fluor 568 (Invitrogen; A21090; 1:750) with a goat 
anti-human Fc IgG(specific) secondary (Thermo Scientific; 31125; 1:750) followed by a 
mouse anti-goat IgG, Alexa fluor 568 (1:750) for 45 minutes at room temperature as 
mentioned in the methods.  See Figure 1 for examples. 
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